DAMORA THERAPEUTICS, INC. Other Comprehensive Income (Loss), Net of Tax
DAMORA THERAPEUTICS, INC. (DMRA) reported Other Comprehensive Income (Loss), Net of Tax of -$22.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$22.00K, a 104.32% decline year-over-year.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$48.00K, a 123.65% decline year-over-year.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was -$21.00K.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $14.00K, a 97.01% decline year-over-year.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2025 was $705.00K.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$283.00K, a 145.35% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $624.00K, a 721.05% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was $76.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.00K 10-Q · filed 2026-08-10 | -$70.00K 10-Q · filed 2026-08-10 | -$91.00K derived: sum of 3 quarters · filed 2026-08-10 | -$77.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$48.00K 10-Q · filed 2026-05-12 | -$69.00K derived: sum of 2 quarters · filed 2026-05-12 | -$55.00K derived: sum of 3 quarters · filed 2026-05-12 | $454.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$7.00K derived: sum of 2 quarters · filed 2026-03-19 | $502.00K derived: sum of 3 quarters · filed 2026-08-10 | $705.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $14.00K 10-Q · filed 2025-11-06 | $523.00K derived: sum of 2 quarters · filed 2026-08-10 | $726.00K 10-Q · filed 2025-11-06 | $158.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $509.00K 10-Q · filed 2026-08-10 | $712.00K 10-Q · filed 2026-08-10 | $144.00K derived: sum of 3 quarters · filed 2026-08-10 | $612.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $203.00K 10-Q · filed 2026-05-12 | -$365.00K derived: sum of 2 quarters · filed 2026-05-12 | $103.00K derived: sum of 3 quarters · filed 2026-05-12 | -$26.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$100.00K derived: sum of 2 quarters · filed 2026-03-19 | -$229.00K derived: sum of 3 quarters · filed 2026-03-19 | -$283.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $468.00K 10-Q · filed 2025-11-06 | $339.00K derived: sum of 2 quarters · filed 2025-11-06 | $285.00K 10-Q · filed 2025-11-06 | $619.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$129.00K 10-Q · filed 2025-08-05 | -$183.00K 10-Q · filed 2025-08-05 | $151.00K derived: sum of 3 quarters · filed 2025-08-05 | $334.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$54.00K 10-Q · filed 2025-05-08 | $280.00K derived: sum of 2 quarters · filed 2025-05-08 | $463.00K derived: sum of 3 quarters · filed 2025-05-08 | $453.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $517.00K derived: sum of 2 quarters · filed 2025-03-19 | $507.00K derived: sum of 3 quarters · filed 2025-03-19 | $624.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $183.00K 10-Q · filed 2024-11-01 | $173.00K derived: sum of 2 quarters · filed 2024-11-01 | $290.00K 10-Q · filed 2024-11-01 | $1.97M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | -$10.00K 10-Q · filed 2024-08-12 | $107.00K 10-Q · filed 2024-08-12 | $1.79M derived: sum of 3 quarters · filed 2024-08-12 | $1.36M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $117.00K 10-Q · filed 2024-04-29 | $1.80M derived: sum of 2 quarters · filed 2024-04-29 | $1.37M derived: sum of 3 quarters · filed 2024-04-29 | $568.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $1.25M derived: sum of 2 quarters · filed 2024-03-08 | $451.00K derived: sum of 3 quarters · filed 2024-03-08 | $76.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$426.00K 10-Q · filed 2023-11-06 | -$1.23M derived: sum of 2 quarters · filed 2023-11-06 | -$1.60M 10-Q · filed 2023-11-06 | -$1.84M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$804.00K 10-Q · filed 2023-07-31 | -$1.18M 10-Q · filed 2023-07-31 | -$1.41M derived: sum of 3 quarters · filed 2023-07-31 | -$1.75M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | -$375.00K 10-Q · filed 2023-04-28 | -$606.00K derived: sum of 2 quarters · filed 2023-04-28 | -$941.00K derived: sum of 3 quarters · filed 2023-04-28 | |
| 2021-12-31 | -$231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$566.00K derived: sum of 2 quarters · filed 2023-03-09 | -$994.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$335.00K 10-Q · filed 2022-11-08 | -$763.00K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |